Stephanie Schalm

Company: Kymera Therapeutics

Job title: Senior Director - Oncology

Bio:

Seminar: Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors 

For more information on this session, please download the full event guide.

Day: Day Two